步长制药表示，未来将积极寻求新的合作发展机遇，继续在科技创新、产品质量提升、社会责任履行等 方面持续发力，努力为我国医药健康产业高质量发展、增进人民群众健康福祉作出新的更大贡献。 作为深耕大健康领域的领军企业代表，步长制药（603858）董事长赵涛受邀出席大会并在"生物科技领 袖论坛"上作主旨发言。他围绕中药材标准化种植、企业核心业务布局、行业发展趋势及国际化战略等 发表重要观点，引发媒体及现场嘉宾关注。 随着人们对美好健康生活的需求增加，特别是全球化背景下中国老年人口数量增长(每位老年人的医疗 健康消费需求约为普通人的三倍)，未来医疗资源需求将呈现大幅增长趋势。赵涛表示，我国非常重视 生物医药和创新药发展，密集出台多项政策，从技术跨境转化与资本流动等多维度赋能生物医药和创新 药产业发展。步长制药正在积极构建专利中药、生化药、大健康产业协同发展格局，加速布局生物医 药、疫苗产业新赛道。 中证报中证网讯(王珞)近日，由香港生物科技协会主办的2025年香港国际生物科技论坛暨展览(简 称"BIOHK2025")于9月10日在香港会议展览中心开幕。本届展会汇聚来自25个国家及地区的顶尖嘉宾， 设置多场主题报告、50余 ...

Group 1 - The Chinese innovative drug industry is experiencing robust growth driven by policy support, talent return, and engineer dividends [1] - The number of original innovative drug research pipelines has increased from 124 in 2015 to 704 in 2024, ranking first globally [1] - Chinese companies are accelerating their shift towards original innovation, with the number of self-researched FIC innovative drugs entering clinical trials rising from 9 in 2015 (less than 10% globally) to 120 in 2024 (over 30%) [1] Group 2 - Chinese pharmaceutical companies are active in global business development transactions, with total licensing agreements reaching $51.9 billion in 2024, including an upfront payment of $4.1 billion [1] - The diversity of transaction types is increasing, with ADC drugs accounting for 20% and small nucleic acid drugs achieving over $6 billion in significant transactions [1] - Over 60% of preclinical License-out projects indicate enhanced international attractiveness of early-stage research assets [1] Group 3 - The Vaccine ETF (159643) tracks the Vaccine Biotechnology Index (980015), which is compiled by China Securities Index Co., Ltd., selecting listed companies involved in vaccine research, production, and sales [1] - The Vaccine Biotechnology Index reflects the overall performance of listed companies in China's vaccine industry, characterized by high growth and innovation [1]